Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Libevitug in Chronic Hepatitis B and D Co-infection
NCT05674448Phase 2Terminated
- Sponsor
- Huahui Health
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Libevitug in Chronic Hepatitis B (CHB), chronic hepatitis D, sponsored by Huahui Health. Started Aug 2021; status: terminated.
02
Drugs
Libevitug
03
Conditions
Chronic Hepatitis B (CHB)chronic hepatitis D
Beyond the preview
Go deeper on NCT05674448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674448.